Skip to content

Safety Evaluation of HGLG-032406 in Healthy Adult Females

An Open-Label, Single Arm Clinical Study to Evaluate the Safety of HGLG-032406 (IN-100001206) in Healthy Adult Females. - Nil

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/066274
Enrollment
12
Registered
2024-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy adult females within age group of 18 to 40 years. 2.Healthy females as determined by the investigator based on a medical evaluation including medical history, physical examinations, and laboratory examinations. 3.Subjects willing to sign an informed consent document. 4.Subjects willing to adhere to protocol requirements throughout the study period. 5.Subjects who have not participated in any clinical study in the past 30 days

Exclusion criteria

Exclusion criteria: 1.Subjects with known clinically significant serious cardiovascular, neurological, respiratory, gastrointestinal, genitourinary, congenital or any other disorder as determined by the investigator. 2.Women who are pregnant, nursing, or planning a pregnancy during study entry and throughout the duration of the study. 3.Subjects with lactose intolerance (as the IP is to be taken with milk). 4.Subjects with known allergies to any of the ingredients of the investigational product. 5.Subjects with clinically significant pre-existing systemic disease necessitating long-term medications as determined by the investigator. 6.Subjects not willing to refrain from using adequate contraception and hormonal medications one month prior and during the study. 7.Subjects not willing to refrain from taking any other similar supplements during the study period. 8.Subjects not willing to abstain from excessive intake of recreational products like tobacco/pan chewing, smoking, alcohol and any other as determined by the investigator during the study period.

Design outcomes

Primary

MeasureTime frame
To evaluate the safety of Galactagogue in healthy adult females by the following assessments: 1.General Physical Examinations 2.Laboratory Examinations 3.Adverse events Timepoint: Day 1 and Day 7

Secondary

MeasureTime frame
Adverse events (AE): AEs/SAEs will be continuously monitored throughout the duration of the study Timepoint: 7 Days

Countries

India

Contacts

Public ContactDr Soorya Narayan H

Himalaya Wellness Company

dr.anindya@himalayawellness.com8067549920

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026